ArticleThe Journal of clinical investigation2025

Differential BK channel potentiation by vanzacaftor enantiomers enables therapy for modulator-ineligible people with cystic fibrosis.

Nathalie Baumlin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.